Regardless, human CD19 CAR NKT cells against lymphoma (104), and GD2 CAR NKT cells against neuroblastoma (105), have demonstrated preclinical efficacy, with CD19 CAR NKT cells exerting anti-lymphoma activity through both the CAR and the invariant TCR interaction with CD1d. The gene discussed is CD1D; the disease is lymphoma.